Total number of bleeds and ABR at baseline and during 5-year follow-up. (A) Total number of bleeds per participant, per year at baseline and during 5-year follow-up after etranacogene dezaparvovec administration. Participants 1 and 2 did not report any bleeding events during the 5-year follow-up period, and participant 3 experienced 2 bleeds during year 2. No bleeding episodes were reported from year 3 to year 5 for all participants. (B) ABR by participant at baseline and during 5 years of follow-up after etranacogene dezaparvovec administration; ABR was 0 for all participants from years 3 to 5. ∗Data collected retrospectively 1 year before screening from medical records.